Angeles Alvarez Secord, MD
MD
Duke University Medical Center
2301 Erwin Road
Durham,
NC
USA
27705-4699
Papers:
128
Disease stabilization vs. response after bevacizumab treatment in recurrent ovarian cancer: how do we determine clinical efficacy?
226
Sentinel lymph node mapping in women with high risk histology endometrial cancer
273
Findings at laparoscopy, not debulking status, are associated with survival in advanced stage ovarian cancer after neoadjuvant chemotherapy
419
Laparoscopy compared to laparotomy in the management of granulosa cell tumors of the ovary
427
Cost comparison among different genetic testing strategies in women with epithelial ovarian cancer
Patient preferences and treatment decisions in gynecologic cancer
Association between quality of life and clinical outcome in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevacizumab: results from a prospective multicenter phase 3 NRG Oncology/GOG trial
Panel Discussion
A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology / gynecologic oncology group study